+++
title = "Alpha Cognition's ZUNVEYL: A New Hope in Alzheimer's Treatment"
date = "2025-01-30T14:35:34Z"
draft = false
summary = "Alpha Cognition Inc.'s ZUNVEYL, a novel Alzheimer's therapy, promises to revolutionize treatment by minimizing side effects and improving patient adherence, with a strategic launch targeting a $2 billion market opportunity in 2025."
description = "Stonegate Capital Partners initiates coverage on Alpha Cognition Inc. (NASDAQ: ACOG) and its flagship Alzheimer's therapy ZUNVEYL. With FDA approval and upcoming launch, Alpha Cognition aims to provide a well-tolerated treatment option for Alzheimer's patients, addressing the high discontinuation rate due to side effects."
source_link = "https://stonegateinc.reportablenews.com/pr/stonegate-capital-partners-initiates-coverage-on-alpha-cognition-inc-nasdaq-acog"
enclosure = "https://cdn.newsramp.app/reportable/newsimage/fccd8250e89666e72481f8991e684b9b.webp"
article_id = 91206
feed_item_id = 10506
url = "/202501/91206-alpha-cognitions-zunveyl-a-new-hope-in-alzheimers-treatment"
qrcode = "https://cdn.newsramp.app/reportable/qrcode/251/30/camcXRsK.webp"
source = "Reportable"
+++

<p>Alpha Cognition Inc. (NASDAQ: ACOG) has captured the attention of investors and healthcare professionals alike with its innovative Alzheimer's therapy, ZUNVEYL. Recently covered by Stonegate Capital Partners, ZUNVEYL stands out as only the second oral Alzheimer's disease (AD) therapy approved this decade, marking a significant milestone in the treatment of mild-to-moderate Alzheimer's. Its unique formulation bypasses traditional gastrointestinal absorption, thereby reducing common side effects such as nausea, vomiting, and insomnia, which are major reasons patients discontinue current treatments.</p><p>The potential impact of ZUNVEYL is immense, given that Alzheimer's disease affects approximately 7 million people in the United States, leading to 11 million annual prescriptions. A staggering 55% of patients stop their treatment within a year due to severe side effects, highlighting a critical unmet need that ZUNVEYL is poised to address. Alpha Cognition is strategically targeting the long-term care (LTC) market for the launch of ZUNVEYL in the first quarter of 2025, a sector that accounts for about 36% of Alzheimer's prescriptions and represents a $2 billion opportunity.</p><p>Alpha Cognition's preparation for ZUNVEYL's launch includes a dedicated 33-person sales team covering over 80% of LTC providers, with an 88% reported willingness among physicians to prescribe the medication. Beyond Alzheimer's, the company is investigating ZUNVEYL's efficacy in treating traumatic brain injury (TBI) in collaboration with the Department of Defense, potentially opening new avenues for the drug's application.</p><p>Financially, Alpha Cognition appears well-positioned, backed by a management team with over 350 years of combined commercial experience. A recent $44 million licensing agreement with China Medical Systems Holdings underscores the global potential of ZUNVEYL. Stonegate Capital Partners' valuation analysis projects a promising future for Alpha Cognition, with a potential valuation range of $27.62 to $38.44, reflecting strong investor confidence in the company's prospects.</p><p>As the search for effective Alzheimer's treatments continues, ZUNVEYL emerges as a beacon of hope, offering a transformative approach that could significantly improve patient quality of life and adherence to treatment. With its strategic market positioning and potential for broader applications, ZUNVEYL is set to make a lasting impact on the Alzheimer's treatment landscape.</p>